Provided by Tiger Fintech (Singapore) Pte. Ltd.

BEIGENE

139.700
-0.500-0.36%
Volume:4.41M
Turnover:614.56M
Market Cap:195.72B
PE:-38.22
High:141.500
Open:137.600
Low:137.400
Close:140.200
Loading ...

BeiGene Is Maintained at Overweight by JP Morgan

Dow Jones
·
6 hours ago

BeiGene Price Target Maintained With a $348.00/Share by Guggenheim

Dow Jones
·
10 Apr

Hong Kong Stocks Reverse Early Losses to End Higher; Pharma Stocks Slide

MT Newswires Live
·
09 Apr

Hong Kong Pharma Stocks Decline as Trump Threatens Tariffs on Imported Drugs

MT Newswires Live
·
09 Apr

BeiGene Initiated at Outperform by RBC Capital

Dow Jones
·
07 Apr

RBC Initiates BeiGene at Outperform With $312 Price Target

MT Newswires Live
·
07 Apr

BeiGene to Discontinue Potential Lung Cancer Treatment Study

MT Newswires Live
·
03 Apr

BeiGene Scraps Ociperlimab Lung-Cancer Drug Candidate

Dow Jones
·
03 Apr

BeiGene Says EMA Panel Recommends Approval of Tevimbra for Lung Cancer

MT Newswires Live
·
31 Mar

BeiGene Net Loss Narrows 27% in 2024

MT Newswires Live
·
28 Mar

BeiGene Shareholder Hillhouse Pares Stake in Cancer Drug Company

MT Newswires Live
·
10 Mar

BeiGene Commences New Offering Period for Employee Share Purchase Plan

MT Newswires Live
·
07 Mar

BeiGene Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
05 Mar

BeiGene Says FDA Approves Tevimbra for Esophageal Cancer First-Line Treatment

MT Newswires Live
·
04 Mar

BofA Securities Upgrades BeiGene to Buy, Price Target is $320

MT Newswires Live
·
03 Mar

Nomura Adjusts BeiGene Price Target to $347.02 From $316.65, Maintains Buy Rating

MT Newswires Live
·
03 Mar

BeiGene's Q4'24 Loss Narrows

MT Newswires Live
·
03 Mar

BeiGene Expects Up to 38-Billion-Yuan Revenue in 2025; Shares Jump 7%

MT Newswires Live
·
28 Feb

Stock Track | BeiGene Soars 7.74% as Strong Revenue Growth Fuels Optimism

Stock Track
·
28 Feb

BUZZ-BeiGene Hong Kong shares hit over 3-year high as revenue jumps

Reuters
·
28 Feb